Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation

Hypertension. 2021 Jun;77(6):1825-1844. doi: 10.1161/HYPERTENSIONAHA.121.16975. Epub 2021 May 12.

¹ Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, Medical Research Foundation, Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia (L.M.L.-G., V.B.M., J.M.N., M.G.K., R.C., D.K., J.C., A.J., L.Y.H., O.A., M.P.S.).
² Kidney Research Centre, The Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa (D.B.).
³ Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany (D.K.).
⁴ Department of Internal Medicine (O.A.), Royal Perth Hospital, Western Australia.
⁵ Departments of Cardiology and Nephrology (M.P.S.), Royal Perth Hospital, Western Australia.
⁶ Neurovascular Hypertension and Kidney Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia (M.P.S.).

Abstract

[Figure: see text].

Keywords: biomarkers; cardiovascular diseases; endothelium; inflammation; vascular diseases.